

Innovative Therapies
for Children with Cancer




We are ready

to actively participate in the development of innovative therapies that will improve the cure rate and quality of life of children with cancer.

Created in 2003, ITCC is a consortium of 49 institutions in 11 European member states and Israel.

ITCC runs a comprehensive clinical and biological early evaluation program of anticancer drugs for children and adolescents, taking into account the unique ethical dimension of running clinical trials in patients with a life-threatening disease.



Austria
CCRI, Vienna

Belgium
Ghent University, Ghent

Denmark
Rigshospitalet, Copenhagen

France
CHU Bordeaux, Bordeaux
Centre Oscar Lambret, Lille
Centre Léon Bérard, Lyon
La Timone, Marseille
CHU Nantes, Nantes
Trousseau, Paris
Hopital Robert Debré, Paris
Institut Curie, Paris
CHU Toulouse, Toulouse
CHU Nancy, Vandoeuvre
Institut Gustave Roussy, Villejuif

Ireland
Our Lady's Hospital
for Sick Children,
Dublin

Germany
UniversitätsKlinikum, Essen
Heidelberg University Hospital, Heidelberg
Charité, OHC, Berlin
UniversitätsKlinikum, Frankfurt
Pädiatrische Hämatologie
und Onkologie Zentrum, Freiburg
Hannover Medical School, Hannover
University Medical Center Schleswig-Holstein, Kiel
UniversitätsKlinikum, Münster
Olgahospital Padiatrisches, Stuttgart


Israel
Schneider Children's
Medical Center of Israel,
Petah-Tikva

Italy
Gaslini Institute, Genova
Istituto Nazionale Tumori, Milano
Ospedale San Gerardo, Monza
Azienda Ospedaliera, Padova
Università Cattolica del
Sacro Cuore, Roma
Ospedale Bambin Gesù, Roma
Università di Torino, Torino

United Kingdom
Birmingham Children's Hospital, Birmingham
Royal Hospital, Bristol
Addenbrookes Hospital, Cambridge
Yorkhill Hospital, Glasgow
St James University Hospital, Leeds
Great Ormond Hospital, London
Children's Hospital, Manchester
Newcastle University, Newcastle
Royal Marsden, Sutton
Alder Hey Children's NHS Foundation Trust, Liverpool

The Netherlands
AMC, Amsterdam
Erasmus, Rotterdam

Each year, **4500 patients** with cancer are newly diagnosed in ITCC centers:



20% of them experience recurrence of their disease and are offered to participate to ITCC trials.

More than **450 health professionals** work in the ITCC early phase teams in the ITCC institutions:

1. To develop more effective new anticancer compounds in early drug development for children and adolescents
2. To introduce new safe and effective agents (including combinations) in standard care in collaboration with the European Clinical Trials groups
3. To cooperate with academia, regulatory bodies, pharmaceutical industries and parents to promote safe and effective innovative treatments for children and adolescents with cancer.

Executive Committee




Switzerland
University Children's Hospital,
Zurich

Spain
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Universitario La FE, Valencia
Hospital Nino Jesus, Madrid
Hospital Sant Joan de Deu, Barcelona

From 2003 to 2014, 1109 children and adolescents participated in 35 phase I and II trials exploring 37 new anticancer drugs:

First in child trials, phase 1a and 1b trials, phase 2 trials including innovative design and methodology.



Sponsoring Clinical trials

A consortium of **5 ITCC institutions** was created in **2014** to share the administrative burden of European sponsorship for ITCC academic-trials and establish harmonized procedures for ITCC academic trials:



ITCC academic trials are run in partnership with Pharmaceutical companies and / or through funding by European and national grants as well as charities.

Since 2003, ITCC has run 11 investigator driven clinical trials this new structure will allow ITCC:

- To sponsor and run high-quality early clinical trials according to GCP and ethical grounds across Europe and beyond
- To reduce the time needed for launching ITCC academic trials
- To monitor the performance of ITCC centers

Expertise

ITCC has skills and a broad expertise in pediatric oncology, biology and drug development.


Since 2007, ITCC has contributed to more than 26 PIPs

By 2020, more than one out of 2 patients with no curable relapse in ITCC centers will have access to at least one innovative therapy.

THREE PILLARS

- 1 Precision Cancer Medicine program : Individual molecular tumor (and host) profiling for driving the therapeutic proposal in relapse and creating a large clinical-biological database
- 2 Target validation and preclinical evaluation adapted to each target and compound on relevant pediatric tumor models
- 3 Target/pathway discovery: new pathways and mechanisms of resistance through cooperation with European basic scientists and research labs and access to the shared genomic ITCC database

STRATEGY



Partnership with Imagine for Margo :

ITCC and Imagine for Margo have established a 3 years partnership, since 2012, Imagine for Margo has co-funded three projects :

- VINILO in low grade glioma,
- BEACON in neuroblastoma
- BIOMEDE in diffuse intrinsic pontine glioma.

Other Charities as big as I4M such as Cancer Research United Kingdom (UK) and Kika co-funded ITCC projects run by ITCC institutions.




International cooperation :

ITCC cooperates with TACL, POETIC, C17, ACTC and COG phase I consortium to run early trial in very rare populations of children.

Multi stakeholder cooperation between academia, parents, industry and regulators is essential to improve oncology drug development for children and adolescents with cancer.

ITCC, with SIOPE and CDDF created the Multi-stakeholder pediatric oncology platform within the FP7 network of excellence ENCCA




Executive Committee members:

- Pr. Gilles Vassal, President
- Pr. Bruce Morland, Vice President
- Dr. Birgit Geoerger,
- Pr. Pamela Kearns,
- Pr. André Baruchel
- Pr. François Doz
- Pr. Andrew Pearson
- Pr. Stefan Pfister
- Pr. Michel Zwaan

@ Itcc.network@gmail.com

https://twitter.com/itcc_eu

http://www.itcc-consortium.org



“Innovative thinking, innovative results”

“Address unmet needs”

“Expertise for innovative strategy”

“Category 1 EnprEMA Network”



“ Precision Cancer Medicine ”

“Expertise in drug development & early drug trials”

“ Identifying and training the future key opinion
leaders in the field of oncology drug development
in children & adolescents ”

ITCC Office

114 rue Edouard Vaillant
94805 Villejuif cedex

Tel : +33142116033

Fax : +33142114963

Innovative Therapies
for Children with Cancer



Innovative Therapies
for **Children with Cancer**



BY

COMMUNICATION

CED-WEB

Internet & Com. graphique